NCT04930536View on ClinicalTrials.gov

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

PHASE4CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

July 14, 2021

Primary Completion Date

May 2, 2023

Study Completion Date

May 2, 2023

Conditions
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Interventions
DRUG

Acalabrutinib capsule

The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily

Trial Locations (15)

122001

Research Site, Gurugram

160012

Research Site, Chandigarh

380009

Research Site, Ahmedabad

400010

Research Site, Mumbai

400012

Research Site, Mumbai

500019

Research Site, Hyderabad

500033

Research Site, Hyderabad

560017

Research Site, Bangalore

560064

Research Site, Bangalore

560099

Research Site, Bengaluru

682041

Research Site, Kochi

700160

Research Site, Kolkata

781032

Research Site, Guwahati

141 008

Research Site, Ludhiana

110 085

Research Site, New Delhi

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY